MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology, Inc. (MAIA) — VMCI valuation read

MAIA screens at VMCI 44/100, a 6-point gap below the Healthcare sector median (50). For a mid-cap MAIA Biotechnology, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

MAIA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: MAIA trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -2.1x leaves covenant headroom, which sets the rate-cycle exposure for MAIA Biotechnology, Inc..

MAIA rose 3.5% over the trailing 7 days, with a +7.8% read on a 30-day basis.